Bladder Cancer — Vax-Before-Travel

Fact checked by Robert Carlson, MD

Apr 23

3 min read

US FDA Approves IL-15 Superagonist for Treating Bladder Cancer

ImmunityBio Anktiva N-803 Plus BCG vaccination is an FDA approved bladder cancer therapy

bladder cancer vaccine

Fact checked by Robert Carlson, MD

Feb 5

4 min read

Bladder Cancer Vaccine Therapy Offers Favorable Risk-Benefit Ratio

N-803 plus BCG bladder cancer vaccine therapy candidate has Prescription Drug User Fee Act date of April 23, 2024

BCG vaccine cancer

Fact checked by Holly Lutmer PharmD

Oct 23

5 min read

Non-Muscle-Invasive Bladder Cancer Vaccine Candidate Competes Resubmission to US FDA

Anktiva N-803 is a first-in-class IL-15 superagonist plus BCG vaccine

Bladder cancer vaccine 2023

Fact checked by Robert Carlson, MD

Jan 9

4 min read

Bladder Cancer Treatment Innovates in the Right Direction

N-803 Plus BCG in Patients with Bladder Cancer found effective

TICE BCG vaccine production

Fact checked by Robert Carlson, MD

Jan 16

4 min read

NantKwest ‘Triangle-Offense’ Induces Immunogenic Cell Death

NantKwest Inc. believes a common treatment protocol that harnesses both the natural-killer cell and the T cells could be effective in treating cancer across multiple tumor types

colorful abstract design with triangles